<DOC>
	<DOCNO>NCT00191139</DOCNO>
	<brief_summary>To assess 2 year survival patient Stage III unresectable non-small cell lung cancer receive consolidation gemcitabine gemcitabine plus docetaxel follow concurrent chemotherapy radiation .</brief_summary>
	<brief_title>Gemcitabine Gemcitabine Plus Docetaxel After Cisplatin , Etoposide Radiation Non Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>histologic cytologic proof single primary nonsmall cell lung cancer No prior chemotherapy radiation therapy prior malignancy pregnancy breastfeed serious concomitant systemic disorder unintentional weight loss great 10 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>